Acceptability Study of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Type 2 Diabetes and Dyslipidemia

NCT00490178 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2
Dyslipidemia

Interventions

DRUG: Fenofibrate 80 mg and metformin 1000 mg (fixed combination)

Sponsor

Solvay Pharmaceuticals